Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.

ABSTRACT:

Background

Therapeutic treatments for schizophrenia do not alleviate symptoms for all patients and efficacy is limited by common, often severe, side-effects. Genetic studies of disease can identify novel drug targets, and drugs for which the mechanism has direct genetic support have increased likelihood of clinical success. Large-scale genetic studies of schizophrenia have increased the number of genes and gene sets associated with risk. We aimed to examine the overlap between schizophrenia risk loci and gene targets of a comprehensive set of medications to potentially inform and improve treatment of schizophrenia.

Methods

We defined schizophrenia risk loci as genomic regions reaching genome-wide significance in the latest Psychiatric Genomics Consortium schizophrenia genome

SUBMITTER: Ruderfer DM 

PROVIDER: S-EPMC4982509 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature